Nymox Pharmaceutical Corporation, a biopharmaceutical company, engages in the research and development of drugs for the aging population in Canada, the United States, Europe, and internationally. Its lead drug candidate is Fexapotide Triflutate (NX-1207), which has completed Phase III clinical trials for the treatment of benign prostatic hyperplasia, and Phase II clinical trials for low grade localized prostate cancer, as well as is in preclinical studies for hepatocellular carcinoma. The company also develops and markets NicAlert and TobacAlert tests that use urine or saliva to detect use of tobacco products. In addition, it offers AlzheimAlert, a proprietary urine assay that aids physicians in the diagnosis of Alzheimer's disease, as well as researches and develops drug treatments for Alzheimer's disease. The company was founded in 1989 and is headquartered in Nassau, the Bahamas.
Revenue of Nymox Pharmaceutical Corporation (NYMX)
Revenue in 2022 (TTM): $
According to Nymox Pharmaceutical Corporation's latest financial reports the company's current revenue (TTM) is $. The revenue is the total amount of income that a company generates by the sale of goods or services. Unlike with the earnings no expenses are subtracted.
Revenue history of Nymox Pharmaceutical Corporation
Annual Revenue
| Year | Revenue | Gross Profit | Ebitda | Income Before Tax | Net Income |
|---|---|---|---|---|---|
| 2022 | $ | $ | $-6,289,000 | $-6,576,000 | $-6,571,000 |
| 2021 | $ | $ | $-12,242,000 | $-12,537,000 | $-12,576,000 |
| 2020 | $5 K | $1,000 | $-11,426,000 | $-11,738,000 | $-11,780,000 |
| 2019 | $116 K | $58 K | $-12,547,000 | $-13,162,000 | $-13,200,000 |
| 2018 | $299 K | $161 K | $-10,566,000 | $-10,594,000 | $-10,594,000 |
| 2017 | $224 K | $75 K | $-13,223,000 | $-13,429,000 | $-13,429,000 |
| 2016 | $283.61 K | $110.59 K | $-12,862,233 | $-13,109,608 | $-13,109,608 |
| 2015 | $2.76 M | $2.6 M | $-17,654,302 | $-17,893,863 | $-17,893,863 |
| 2014 | $2.95 M | $2.78 M | $-4,788,704 | $-4,646,093 | $-4,594,093 |
| 2013 | $3.36 M | $2.87 M | $-4,872,453 | $-4,908,603 | $-4,908,603 |
| 2012 | $3.07 M | $2.82 M | $-7,578,058 | $-7,627,589 | $-7,627,589 |
| 2011 | $3.11 M | $2.82 M | $-9,597,794 | $-9,652,389 | $-9,652,389 |
| 2010 | $692.64 K | $375.7 K | $-6,938,732 | $ | $-6,956,033 |
| 2009 | $415.98 K | $169.89 K | $-4,896,678 | $ | $-5,130,074 |
| 2008 | $428.41 K | $166.08 K | $-4,065,281 | $ | $-4,590,345 |
| 2007 | $433.93 K | $192.49 K | $-4,759,946 | $ | $-5,290,431 |
| 2006 | $442.86 K | $201.46 K | $-4,367,392 | $-4,893,685 | $-4,893,685 |
| 2005 | $426.28 K | $218.94 K | $-3,101,270 | $ | $-3,584,528 |
| 2004 | $321.95 K | $136.38 K | $-3,271,153 | $ | $-3,745,625 |
| 2003 | $200.13 K | $76.67 K | $-3,924,416 | $ | $-4,363,699 |
| 2002 | $361.75 K | $145.11 K | $-3,043,583 | $-3,375,052 | $-3,422,019 |
| 2001 | $235.29 K | $103.38 K | $-2,934,191 | $-3,049,504 | $-3,049,504 |
| 2000 | $225.87 K | $138.42 K | $-3,634,000 | $-4,023,979 | $-4,023,979 |
| 1999 | $153.25 K | $153.25 K | $-3,301,812 | $-3,345,391 | $-3,314,296 |
| 1998 | $100.6 K | $100.6 K | $-4,728,369 | $-4,426,558 | $-4,527,162 |
| 1997 | $99.9 K | $99.9 K | $-3,296,755 | $ | $-3,496,558 |